Back to top

crispr: Archive

Zacks Equity Research

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

Devoid of marketed drugs, investors' focus will be on CRISPR Therapeutics' (CRSP) pipeline, specifically its lead candidate exa-cel, in its fourth-quarter earnings.

VRTXNegative Net Change SNDXPositive Net Change CRSPNegative Net Change RCUSPositive Net Change

Zacks Equity Research

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

Vertex Pharmaceuticals' (VRTX) four-quarter 2022 earnings and sales beat estimates. VRTX also issues better-than-expected revenue guidance for 2023.

VRTXNegative Net Change MRNAPositive Net Change CRSPNegative Net Change RCUSPositive Net Change

Zacks Equity Research

Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

On Vertex Pharmaceuticals' (VRTX) Q4 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.

VRTXNegative Net Change SNDXPositive Net Change CRSPNegative Net Change RCUSPositive Net Change